These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
426 related articles for article (PubMed ID: 31118200)
21. MiR-873/PD-L1 axis regulates the stemness of breast cancer cells. Gao L; Guo Q; Li X; Yang X; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Xi T; Zheng L EBioMedicine; 2019 Mar; 41():395-407. PubMed ID: 30803931 [TBL] [Abstract][Full Text] [Related]
22. Employing mesenchymal stem cells to support tumor-targeted delivery of extracellular vesicle (EV)-encapsulated microRNA-379. O'Brien KP; Khan S; Gilligan KE; Zafar H; Lalor P; Glynn C; O'Flatharta C; Ingoldsby H; Dockery P; De Bhulbh A; Schweber JR; St John K; Leahy M; Murphy JM; Gallagher WM; O'Brien T; Kerin MJ; Dwyer RM Oncogene; 2018 Apr; 37(16):2137-2149. PubMed ID: 29367765 [TBL] [Abstract][Full Text] [Related]
23. CCL16 maintains stem cell-like properties in breast cancer by activating CCR2/GSK3β/β-catenin/OCT4 axis. Shen W; Zhang X; Tang J; Zhang Z; Du R; Luo D; Liu X; Xia Y; Li Y; Wang S; Yan S; Yang W; Xiang R; Luo N; Luo Y; Li J Theranostics; 2021; 11(5):2297-2317. PubMed ID: 33500726 [No Abstract] [Full Text] [Related]
24. Transcriptional factor six2 promotes the competitive endogenous RNA network between CYP4Z1 and pseudogene CYP4Z2P responsible for maintaining the stemness of breast cancer cells. Zheng L; Guo Q; Xiang C; Liu S; Jiang Y; Gao L; Ni H; Wang T; Zhao Q; Liu H; Xing Y; Wang Y; Li X; Xi T J Hematol Oncol; 2019 Mar; 12(1):23. PubMed ID: 30832689 [TBL] [Abstract][Full Text] [Related]
25. MicroRNA-205 signaling regulates mammary stem cell fate and tumorigenesis. Chao CH; Chang CC; Wu MJ; Ko HW; Wang D; Hung MC; Yang JY; Chang CJ J Clin Invest; 2014 Jul; 124(7):3093-106. PubMed ID: 24911147 [TBL] [Abstract][Full Text] [Related]
26. MicroRNA-199b-5p impairs cancer stem cells through negative regulation of HES1 in medulloblastoma. Garzia L; Andolfo I; Cusanelli E; Marino N; Petrosino G; De Martino D; Esposito V; Galeone A; Navas L; Esposito S; Gargiulo S; Fattet S; Donofrio V; Cinalli G; Brunetti A; Vecchio LD; Northcott PA; Delattre O; Taylor MD; Iolascon A; Zollo M PLoS One; 2009; 4(3):e4998. PubMed ID: 19308264 [TBL] [Abstract][Full Text] [Related]
27. FSTL1 enhances chemoresistance and maintains stemness in breast cancer cells via integrin β3/Wnt signaling under miR-137 regulation. Cheng S; Huang Y; Lou C; He Y; Zhang Y; Zhang Q Cancer Biol Ther; 2019; 20(3):328-337. PubMed ID: 30336071 [TBL] [Abstract][Full Text] [Related]
28. miR-145 sensitizes breast cancer to doxorubicin by targeting multidrug resistance-associated protein-1. Gao M; Miao L; Liu M; Li C; Yu C; Yan H; Yin Y; Wang Y; Qi X; Ren J Oncotarget; 2016 Sep; 7(37):59714-59726. PubMed ID: 27487127 [TBL] [Abstract][Full Text] [Related]
29. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog. Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805 [TBL] [Abstract][Full Text] [Related]
30. MiR-129-3p promotes docetaxel resistance of breast cancer cells via CP110 inhibition. Zhang Y; Wang Y; Wei Y; Li M; Yu S; Ye M; Zhang H; Chen S; Liu W; Zhang J Sci Rep; 2015 Oct; 5():15424. PubMed ID: 26487539 [TBL] [Abstract][Full Text] [Related]
31. Extracellular Vesicle-Mediated Modulation of Stem-like Phenotype in Breast Cancer Cells under Fluid Shear Stress. Brown SR; Radcliffe ME; Danner JT; Andújar Cruz WJ; Lackey KH; Park HA; Weinman ST; Kim Y Biomolecules; 2024 Jun; 14(7):. PubMed ID: 39062471 [TBL] [Abstract][Full Text] [Related]
32. Exosomes regulate doxorubicin resistance in breast cancer via miR-34a-5p/NOTCH1. Chen NN; Zhou KF; Miao Z; Chen YX; Cui JX; Su SW Mol Cell Probes; 2024 Aug; 76():101964. PubMed ID: 38810840 [TBL] [Abstract][Full Text] [Related]
33. Increased fucosylation has a pivotal role in multidrug resistance of breast cancer cells through miR-224-3p targeting FUT4. Feng X; Zhao L; Gao S; Song X; Dong W; Zhao Y; Zhou H; Cheng L; Miao X; Jia L Gene; 2016 Mar; 578(2):232-41. PubMed ID: 26701615 [TBL] [Abstract][Full Text] [Related]
34. LncRNA SPRY4-IT1 regulates breast cancer cell stemness through competitively binding miR-6882-3p with TCF7L2. Song X; Zhang X; Wang X; Chen L; Jiang L; Zheng A; Zhang M; Zhao L; Wei M J Cell Mol Med; 2020 Jan; 24(1):772-784. PubMed ID: 31736268 [TBL] [Abstract][Full Text] [Related]
35. MiR-222 and miR-29a contribute to the drug-resistance of breast cancer cells. Zhong S; Li W; Chen Z; Xu J; Zhao J Gene; 2013 Nov; 531(1):8-14. PubMed ID: 23994196 [TBL] [Abstract][Full Text] [Related]
36. Doxorubicin and Cisplatin Modulate miR-21, miR-106, miR-126, miR-155 and miR-199 Levels in MCF7, MDA-MB-231 and SK-BR-3 Cells That Makes Them Potential Elements of the DNA-Damaging Drug Treatment Response Monitoring in Breast Cancer Cells-A Preliminary Study. Mizielska A; Dziechciowska I; Szczepański R; Cisek M; Dąbrowska M; Ślężak J; Kosmalska I; Rymarczyk M; Wilkowska K; Jacczak B; Totoń E; Lisiak N; Kopczyński P; Rubiś B Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980974 [TBL] [Abstract][Full Text] [Related]
37. MiR-124 reversed the doxorubicin resistance of breast cancer stem cells through STAT3/HIF-1 signaling pathways. Liu C; Xing H; Guo C; Yang Z; Wang Y; Wang Y Cell Cycle; 2019 Sep; 18(18):2215-2227. PubMed ID: 31286834 [TBL] [Abstract][Full Text] [Related]
38. Combination therapy with epigenetic-targeted and chemotherapeutic drugs delivered by nanoparticles to enhance the chemotherapy response and overcome resistance by breast cancer stem cells. Li SY; Sun R; Wang HX; Shen S; Liu Y; Du XJ; Zhu YH; Jun W J Control Release; 2015 May; 205():7-14. PubMed ID: 25445694 [TBL] [Abstract][Full Text] [Related]
39. Enforced expression of hsa-miR-125a-3p in breast cancer cells potentiates docetaxel sensitivity via modulation of BRCA1 signaling. Xu X; Lv YG; Yan CY; Yi J; Ling R Biochem Biophys Res Commun; 2016 Oct; 479(4):893-900. PubMed ID: 27693788 [TBL] [Abstract][Full Text] [Related]
40. MiR-375 inhibits the stemness of breast cancer cells by blocking the JAK2/STAT3 signaling. Zhao Q; Liu Y; Wang T; Yang Y; Ni H; Liu H; Guo Q; Xi T; Zheng L Eur J Pharmacol; 2020 Oct; 884():173359. PubMed ID: 32738343 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]